Division of Surgical Oncology, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
J Surg Res. 2013 May;181(2):234-41. doi: 10.1016/j.jss.2012.06.047. Epub 2012 Jul 13.
Photodynamic therapy (PDT) is an effective laser treatment for locally treating advanced bile duct carcinoma (BDC). The study objective was to evaluate the synergic effect of PDT using a new photosensitizer, talaporfin sodium (Laserphyrin), in combination with conventional anticancer drug treatments.
The range of the necrotic area, the percentage of apoptosis-positive cells, the vascular endothelial growth factor expression quantification, and the proliferating cell nuclear antigen-labeling index, as treatment effects, were examined in the BDC cell line (NOZ) in vitro and in vivo (4-wk-old male BALB/c mice).
Tumor viability was determined by an in vitro MTS assay. PDT with a single treatment of 5-fluorouracil, gemcitabine, oxaliplatin, and cis-diamminedichloroplatinum showed a significantly lower viability compared with the control or the PDT-alone group (P<0.05). Furthermore, administering PDT combined with two anticancer drugs showed a further decline in the tumor viability. A treatment of PDT combined with oxaliplatin and gemcitabine showed the least viability (P<0.05). Thus, this regimen was administered in the in vivo study. The tumor necrotic area, apoptosis positivity, and the vascular endothelial growth factor expression rate were higher in the PDT with anticancer drugs group compared with those of the other groups (P<0.05). The proliferating cell nuclear antigen-labeling index results in the PDT with the anticancer drugs group were significantly lower than those of the other groups (P<0.05).
A treatment of PDT combined with gemcitabine and oxaliplatin showed the best synergic effect for necrosis, apoptosis, and cytostatic alterations for the treatment of BDC.
光动力疗法（PDT）是一种有效的激光治疗方法，可用于局部治疗晚期胆管癌（BDC）。本研究的目的是评估使用新型光敏剂替拉泊芬钠（Laserphyrin）联合常规抗癌药物治疗的协同作用。
在体外（BDC 细胞系[NOZ]）和体内（4 周龄雄性 BALB/c 小鼠）中，检测 PDT 联合常规抗癌药物治疗的坏死面积范围、凋亡阳性细胞百分比、血管内皮生长因子表达定量和增殖细胞核抗原标记指数作为治疗效果。
通过体外 MTS 测定法测定肿瘤活力。与对照组或 PDT 单独组相比，5-氟尿嘧啶、吉西他滨、奥沙利铂和顺铂单独治疗的 PDT 组的肿瘤活力明显降低（P<0.05）。此外，联合两种抗癌药物进行 PDT 治疗可进一步降低肿瘤活力。联合奥沙利铂和吉西他滨的 PDT 治疗显示出最低的肿瘤活力（P<0.05）。因此，在体内研究中采用了这种方案。与其他组相比，联合抗癌药物的 PDT 组的肿瘤坏死面积、凋亡阳性率和血管内皮生长因子表达率更高（P<0.05）。联合抗癌药物的 PDT 组的增殖细胞核抗原标记指数结果明显低于其他组（P<0.05）。
对于治疗 BDC，PDT 联合吉西他滨和奥沙利铂的治疗显示出最佳的协同坏死、凋亡和细胞抑制改变效果。
